IMVT Immunovant Inc

Price (delayed)

$30.57

Market cap

$4.46B

P/E Ratio

N/A

Dividend/share

N/A

EPS

-$1.88

Enterprise value

$3.83B

Immunovant is a clinical-stage biopharmaceutical company focused on enabling normal lives for patients with autoimmune diseases. Immunovant is developing IMVT-1401, a novel, fully human anti-FcRn monoclonal antibody, as a subcutaneous ...

Highlights
Immunovant's debt has shrunk by 89% YoY and by 55% QoQ
The equity has soared by 70% YoY but it has contracted by 9% from the previous quarter
IMVT's quick ratio has surged by 51% year-on-year but it is down by 39% since the previous quarter
IMVT's net income is down by 23% YoY and by 7% from the previous quarter
Immunovant's EPS has decreased by 10% YoY and by 2.7% QoQ

Key stats

What are the main financial stats of IMVT
Market
Shares outstanding
146.05M
Market cap
$4.46B
Enterprise value
$3.83B
Valuations
Price to earnings (P/E)
N/A
Price to book (P/B)
7.19
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Earnings
Revenue
$0
EBIT
-$258.77M
EBITDA
-$257.41M
Free cash flow
-$214.59M
Per share
EPS
-$1.88
Free cash flow per share
-$1.55
Book value per share
$4.25
Revenue per share
$0
TBVPS
$4.83
Balance sheet
Total assets
$666.37M
Total liabilities
$48.61M
Debt
$138,000
Equity
$617.76M
Working capital
$617.16M
Liquidity
Debt to equity
0
Current ratio
13.7
Quick ratio
13.18
Net debt/EBITDA
2.47
Margins
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Efficiency
Return on assets
-51.3%
Return on equity
-56.1%
Return on invested capital
N/A
Return on capital employed
-41.9%
Return on sales
N/A
Dividend
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A

IMVT stock price

How has the Immunovant stock price performed over time
Intraday
0.76%
1 week
13.69%
1 month
19.6%
1 year
56.77%
YTD
-27.44%
QTD
15.8%

Financial performance

How have Immunovant's revenue and profit performed over time
Revenue
$0
Gross profit
$0
Operating income
-$282.71M
Net income
-$259.34M
Gross margin
N/A
Net margin
N/A
The operating income has declined by 30% year-on-year and by 6% since the previous quarter
IMVT's net income is down by 23% YoY and by 7% from the previous quarter

Growth

What is Immunovant's growth rate over time

Valuation

What is Immunovant stock price valuation
P/E
N/A
P/B
7.19
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Immunovant's EPS has decreased by 10% YoY and by 2.7% QoQ
The equity has soared by 70% YoY but it has contracted by 9% from the previous quarter
The stock's price to book (P/B) is 36% less than its last 4 quarters average of 11.2

Efficiency

How efficient is Immunovant business performance
IMVT's return on equity is up by 8% since the previous quarter but it is down by 7% year-on-year
IMVT's return on assets is up by 7% since the previous quarter but it is down by 6% year-on-year

Dividends

What is IMVT's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A

There are no recent dividends present for IMVT.

Financial health

How did Immunovant financials performed over time
IMVT's total assets has soared by 64% YoY but it is down by 6% QoQ
IMVT's quick ratio has surged by 51% year-on-year but it is down by 39% since the previous quarter
Immunovant's debt is 100% lower than its equity
Immunovant's debt has shrunk by 89% YoY and by 55% QoQ
The equity has soared by 70% YoY but it has contracted by 9% from the previous quarter

All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.